Replies to post #121256 on Biotech Values

[BTH]

I have no idea what you are talking about. '113 is a major opportunity, not a major blunder.

I don't think it's a major blunder either.

All I am saying is that based on the conversations in this thread, a poster is saying that is possible that the only reason Criz works well is because it is hitting other targets and not ALK.

I entirely disagree with his rationale in that I can assure you after the millions PFE has spent on research, and all the clinical data (hundreds of studies in preclinical) on ALK in lung cancer, that ALK *IS* the target for these patients, and it is NOT because it is simply hitting MEK or some other target.